<DOC>
	<DOC>NCT02788721</DOC>
	<brief_summary>The study is a First-in-Human, Phase I, randomized, double-blind, placebo-controlled study evaluating single and multiple ascending oral doses of GLPG2451 and combined multiple doses of GLPG2451 and GLPG2222 in healthy subjects. The purpose of the study is to evaluate safety and tolerability after single ascending oral doses and of multiple doses of GLPG2451 given to healthy subjects compared to placebo as well as of multiple doses of the combination of GLPG2451/GLPG2222 compared to GLPG2451/placebo.</brief_summary>
	<brief_title>First in Human Single and Multiple Dose Study of GLPG2451 and of the Combination of GLPG2222 and GLPG2451</brief_title>
	<detailed_description />
	<criteria>Healthy female subjects of nonchildbearing potential aged18 to 65 years inclusive on day of signing ICF BMI between 1830 kg/m2, inclusive Good health judged by Investigator Discontinuation of all medications except occasional paracetamol at least 2 weeks prior to the first study drug administration nonsmokers and nonusers of any nicotinecontaining products. Negative urine drug screen Able and willing to sign ICF Known hypersensitivity to any drug as determined by the investigator Positive serology for hepatitis B surface antigen or hepatitis C virus or any history of hepatitis History of or current immunosuppressive condition Symptoms of clinically significant illness in the 3 months before the initial study drug administration Presence or having sequelae of gastrointestinal, liver or kidney or other conditions know to interfere with the absorption, distribution, metabolism or excretion of drugs History of malignancy within the past 5 years Clinically relevant abnormalities on ECG Family history of long QT syndrome Clinically relevant abnormalities on vital signs Significant blood loss or having had a transfusion of any blood product within 12 weeks prior to study drug Hemoglobin below 12 g/l Treatment with any drug known to have a welldefined potential for toxicity to a major organ in the last 3 months active drug or alcohol abuse consumption of more than 6 cups coffee a day, or equivalent intolerance to cow milk administration of injectable drug within 30 days prior to study drug prior participation within 8 weeks (or 5 half lives) in a drug of drug/device clinical study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>